380-70-1

Basic information

• Product Name: Propanedioic acid, (acetylamino)[(3-fluorophenyl)methyl]-, diethyl ester
• CAS NO: 380-70-1
• Molecular Formula: C16H20FNO5
• Molecular Weight: 325.337
• Mol File: 380-70-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, (acetylamino)[(3-fluorophenyl)methyl]-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, (acetylamino)[(3-fluorophenyl)methyl]-, diethyl ester(380-70-1)
• EPA Substance Registry System: Propanedioic acid, (acetylamino)[(3-fluorophenyl)methyl]-, diethyl ester(380-70-1)

Safety Data

• Hazardous Substances Data: 380-70-1(Hazardous Substances Data)

Upstream product

• 105-53-3 diethyl malonate 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 

Downstream Products

• 110117-84-5 (R)-2-amino-3-(3-fluorophenyl)propionic acid 
• 453-82-7 N-acetyl-3-fluoro-L-phenylalanine-(N'-phenyl-hydrazide) 
• 330-45-0 N-acetyl-3-fluorophenylalanine methyl ester 
• 456-88-2 3-fluorophenylalanine 
• 19883-77-3 L-3-fluorophenylalanine 
• 1132-68-9 L-4-fluorophenylalanine 
• 17607-28-2 N-acetyl-3-fluoro-D,L-phenylalanine 

Relevant articles and documents

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.

Synthetic and biotransformation studies on prochiral non-proteinogenic amino acids: Diethyl α-acetamido, α-alkylmalonates

Nine diethyl α-acetamido, α-alkylmalonates 3-11 (alkyl=methyl, benzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2,6-difluorobenzyl, 3-trifluoromethylbenzyl, 4-trifluoromethylbenzyi, 2-chlorobenzyl and 3-chlorobenzyl) have been synthesised in three steps starting with diethyl malonate in overall yields of 49-90%. The structures of C-alkylated acetamidomalonates have been established on the basis of their speciral data, the structures of two compounds 9 and 11 are also confirmed on the basis of their X-ray crystallographic studies. Further, the X-ray crystal structure of the chiral monoethyl ester of α-acetamidomalonic acid 1 has been studied. None of our C-alkylated acetamidomalonate has been found to be a substrate for lipase-catalysed enantiodifferentiating deesterification/hydrolysis of the symmetric diester groups.